Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oscar Health, Inc. filings document the public-company disclosures of a healthcare technology and health insurance issuer listed on the New York Stock Exchange under Class A common stock symbol OSCR. Its Form 8-K reports cover operating results, guidance updates, Regulation FD disclosures, material agreements and capital-structure transactions, including credit facilities, convertible notes and debt exchanges.
The company’s proxy materials disclose annual meeting matters, board governance, director elections and executive compensation. Other filings address executive employment arrangements, registered securities, risk language tied to competition, artificial intelligence and machine-learning models, internal controls and the company’s use of technology to support Individual & Family plans, +Oscar services and related healthcare marketplace offerings.
Oscar Health, Inc. (OSCR) filed a Form 8-K on 22 Jul 2025 to notify investors that it has issued a press release containing preliminary second-quarter 2025 results and a revised full-year 2025 outlook. The press release is furnished as Exhibit 99.1 and, per the filing, is not deemed “filed” under Exchange Act Section 18. No quantitative metrics, guidance figures, or additional material events are included in the body of the 8-K. Other than furnishing the exhibit, the company reported no changes to previously disclosed risk factors, transactions, or governance matters.
Oscar Health, Inc. (OSCR) has filed a Form 144 indicating a planned sale of 30,000 common shares through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units (RSUs) on 06/01/2024 and are slated for sale on or about 06/20/2025 on the NYSE. Based on the stated aggregate market value of $563,100, the implied price is roughly $18.77 per share. With 219.163 million shares outstanding, the transaction represents only about 0.014 % of total shares, suggesting minimal dilution or market impact. No other sales by the filer occurred in the past three months, and no adverse information was disclosed in the notice.